Kawasaki disease: Summary of the American Heart Association guidelines

American Family Physician

Volumn 74, Issue 7, 2006, Pages 1141-1150

  Freeman, Alexandra F ^a   Shulman, Stanford T ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN G; INFLIXIMAB; PENTOXIFYLLINE; ULINASTATIN; WARFARIN;

CERVICAL LYMPHADENOPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; DEVELOPED COUNTRY; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; INFECTION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MEDICAL SOCIETY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TREATMENT PLANNING; VASCULITIS;

CHILD; CORONARY ANEURYSM; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; RISK ASSESSMENT;

EID: 33749678228     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279-82.
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [Published correction appears in Pediatrics 2005;115:1118]. Pediatrics 2004;114:1708-33.
3. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80.
4. Stamos JK, Corydon K, Donaldson J, Shulman ST. Lymphadenitis as the dominant manifestation of Kawasaki disease. Pediatrics 1994;93:525-8.
5. Umezawa T, Saji T, Matsuo N, Odagiri K. Chest x-ray findings in the acute phase of Kawasaki disease. Pediatr Radiol 1989;20:48-51.
6. Freeman AF, Crawford SE, Finn LS, Lopez-Andreu JA, Ferrando-Monleon S, Perez-Tamarit D, et al. Inflammatory pulmonary nodules in Kawasaki disease. Pediatr Pulmonol 2003;36:102-6.
7. Falcini F, Cimaz R, Calabri GB, Picco P, Martini G, Marazzi MG, et al. Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. Clin Exp Rheumatol 2002;20:421-6.
8. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126:524-9.
9. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003;(4):CD004000.
10. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
11. Dummer KB, Newburger JW. Acute management of Kawasaki disease. Progress Pediatr Cardiol 2004;19:129-35.
12. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.
13. Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 2003;63:1121-63.
14. McCrindle BW. Cardiovascular complications - coronary artery structure and function. Progress Pediatr Cardiol 2004;19:147-52.
15. Kato H. Cardiovascular complications in Kawasaki disease: coronary artery lumen and long-term consequences. Progress Pediatr Cardiol 2004;19:137-45.